AOD 9604 Peptide Overview
Peptide AOD 9604 is a synthetic analogue of the lipolytic domain of human growth hormone (hGH). Originally developed as a drug to combat obesity, this modified amino acid compound can stimulate the pituitary gland, leading to increased metabolism and fat burning. Studies have shown that AOD 9604 can effectively reduce abdominal fat in both obese individuals and those with average body structures. It has been approved by the FDA for weight loss purposes, making it a rare peptide with this distinction. Additionally, Peptide AOD 9604 has been found to regulate blood sugar levels and improve insulin management without any negative effects on insulin sensitivity. Overall, this peptide greatly enhances the outcomes of dietary restrictions and exercise.
AOD 9604 Peptide Structure
Molecular Weight: 1817.1
PubChem CID: 16131447
Molecular Formula: C78H125N23O23S2
AOD 9604 and Obesity
AOD 9604 is a synthetic version of a specific part of human growth hormone (hGH) that has been examined for its effects on metabolism in obese rats. It has been discovered that AOD 9604 selectively activates the breakdown of fat in fat cells, leading to a reduction in body fat and weight loss. In a 12-week clinical trial, participants who received AOD-9604 lost an average of 2.6 kg, while those in the placebo group lost only 0.8 kg.
Administering an oral dose of AOD9604 at 500 microg/kg body weight for 19 days reduced body weight gain by over 50% compared to the control group. Long-term treatment with AOD9604 did not negatively impact the insulin sensitivity of the animals. These findings suggest that AOD 9604, a derivative of the lipolytic domain of hGH, has the potential to be developed into a safe and effective oral therapy for obesity. Overall, AOD 9604 significantly enhances the outcomes of dietary restrictions and exercise.
AOD 9604 and Lipolysis
AOD9604 is a peptide fragment derived from human growth hormone. It has been studied for its ability to activate lipolysis in adipose tissue, making it a potential treatment for obesity and metabolic disorders. Some important findings from research on AOD9604 include:
- A study on genetically obese rats and mice found that AOD9604 reduced body weight without negatively affecting glycemic control.
- In a 12-week clinical trial, subjects who received AOD9604 lost an average of 2.6 kg, compared to 0.8 kg in the placebo group.
- Six human clinical trials, including both intravenous and oral dosing studies, confirmed the safety and tolerability of AOD9604.
- AOD9604 has been shown to improve glucose tolerance and insulin sensitivity without impacting heart rate.
- Initial trials found that AOD9604 produced weight loss similar to human growth hormone, particularly targeting abdominal fat.
Overall, AOD9604 shows promise as a therapy for obesity and metabolic disorders, with a good safety profile in human studies.
AOD 9604 and Cartilage Repair
In a study using a collagenase-induced knee osteoarthritis rabbit model, it was discovered that intra-articular AOD9604 injections can improve cartilage regeneration and decrease joint pain. When combined with peptide BPC 157, AOD 9604 exhibits enhanced cartilage repair and regenerative properties.
What is AOD 9604?
AOD 9604 is a peptide fragment of the C-terminus of human growth hormone (hGH) that has been studied for its metabolic actions, particularly in relation to fat burning and obesity.
What are the Benefits of AOD 9604?
Here are some of the key benefits of AOD 9604:
- AOD 9604 is a synthetic analog of hGH that exhibits fat-reducing activity without adverse effects.
- It shows promise as a treatment for obesity, without impacting insulin sensitivity.
- AOD 9604 can enhance fat burning, promote muscle growth, and reduce muscle breakdown.
- It has been found to help with bone and cartilage repair, osteoarthritis, and hypercholesterolemia.
- AOD 9604 has an excellent safety profile and has obtained Human GRAS (Generally Recognized as Safe) status in the USA.
- It is an FDA-approved peptide used for weight loss.
What is the Mechanism of Action of AOD 9604?
The mechanism of action of AOD 9604, a peptide therapy, is not fully understood, but it shares some biological effects with human growth hormone (hGH). Here are some key points about how AOD 9604 works:
- AOD 9604 speeds up metabolism and promotes fat burning by stimulating the pituitary gland.
- It has its own mechanism of action that activates degradation and fat burning, independent of the hGH receptor.
- AOD 9604 interacts with the beta-adrenergic pathway, specifically the beta(3)-adrenergic receptors (beta(3)-AR), which are involved in breaking down fat.
- By increasing the expression of beta(3)-AR RNA, AOD 9604 enhances lipolysis and aids in weight loss.
- Long-term treatment with AOD 9604 can reduce body weight and body fat in obese mice.
- It targets areas of the body with high fat levels and stimulates the breakdown of fats and lipids.
- AOD 9604 also inhibits lipogenesis, the process that forms fat, reducing the amount of triglycerides in the body.
Overall, AOD 9604 stimulates lipolysis, increases the breakdown of fats, and inhibits lipogenesis to reduce the formation of new fat cells. It is important to note that while AOD 9604 has shown promising results in studies, further research is needed to fully understand its mechanism of action.
Can I use AOD9604 and AOD-9604 interchangeably?
Yes, AOD9604 and AOD-9604 are the same compound. They both refer to the peptide fragment of HGH known as AOD 9604.
What is the role of AOD 9604 in lipid metabolism?
AOD 9604 has been shown to have effects on lipid metabolism following chronic treatment. It may influence the breakdown and utilization of lipids in the body, potentially contributing to its fat-burning properties.
What were the phase 2b clinical trials for AOD 9604?
The phase 2b clinical trials for AOD 9604 were conducted to assess the effectiveness of the drug in treating obesity. AOD 9604 is a drug that activates lipolysis in adipose tissue and is derived from a peptide fragment of human growth hormone (hGH 177-191). The trials involved 300 obese patients at five trial sites over a 12-week period. As of June 2004, more than one-third of the patients had completed the treatment. The OPTIONS study included 24 weeks of randomized double-blind treatment with either the drug or a placebo, with the main goal of measuring weight loss at 12 weeks. In a 12-week randomized clinical trial, patients who received AOD-9604 (1 mg/d) lost an average of 2.6 kg, while those in the placebo group lost only 0.8 kg. The drug demonstrated high success rates in the trials.
Where to Buy AOD 9604
Limitless Life Nootropics is the leading online source to buy AOD 9604. Our extensive range of products undergoes rigorous third-party testing to verify the sequential signatures of all peptides available for sale. This meticulous process ensures that customers consistently receive pharmaceutical-grade products of the utmost purity. With our commitment to quality, most orders are promptly sent out on the same day they are placed, accompanied by our unwavering dedication to providing exceptional customer service.